BioSpace News Archive

ReCor Medical, Inc. (“ReCor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., today announced late-breaking data from its RADIANCE II U.S. FDA IDE pivotal trial will be presented at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation.

Danaher Corporation announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company’s third quarter 2022 performance in a presentation at its investor and analyst event.

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, will participate in a fireside chat at the upcoming Guggenheim Nantucket Therapeutics Conference.

IDEAYA Biosciences, Inc. announced that it intends to offer and sell up to $80.0 million of shares of its common stock in an underwritten public offering.

Clinical Enterprise, Inc. d/b/a empowerDX, who offers the at-home Celiac Risk Gene Test, announced today that they have entered into an exclusive partnership with NIMA Partners, the makers of Gluten Sensor and Gluten Capsules for the detection of gluten in food particles.

ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, announced today it will participate in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022.

Qurient Co. Ltd. (KRX: 115180), a clinical-stage biotech company based in Korea, today announced that the company has entered into a clinical collaboration agreement with MSD (Merck & Co., Inc., Rahway, NJ., USA), for clinical study of Q901, a selective CDK7 inhibitor in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab).

Mallinckrodt plc, a global specialty pharmaceutical company, announced that the U.S. Food and Drug Administration approved Terlivaz® for injection.

Increasing demand for gastrointestinal devices in the online retainling business coupled with high investments in R&D of gastrointestinal devices are fueling the market growth.

Developments in biosimilars, increasing prevalence rate of Ulcerative Colitis, and changing lifestyle have resulted in boosting the Ulcerative Colitis Drug market.